FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

2.

Year in Review: Non-Small Cell Lung Cancer

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

Independent Risk Factors for "Deaths of Despair" Found.

5.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot